Accurate Noninvasive Assessment of Myocardial Iron Load in Advanced Heart Failure Patients

Table 1

Clinical characteristics of the study group.

	Heart failure patients ()
Age (yrs)	51 (6.5)
Men/women,	25/8
Etiology: idiopathic/ischemic/other,	10/21/2
NYHA functional class: III/IV,	15/18
LVESV (ml)/LVEDV (ml)/LVEF (%)	189 (95)/245 (83)/22 (11)
RVD (mm)	32 (10)
Mean PWP/mean PAP (mmHg)	23 (9)/
PVR/SVR (W.u.)	3.36 (1.2)/21.9 (6.2)
CI (l/min/m^2)	1.93 (0.64)
Red blood cells (ml/μl)/hematocrit (%)	4.5 (0.6)/39.7 (5.3)
Mean corpuscular volume (fl)	88.4 (7.1)
Hemoglobin (g/dl)/mean corpuscular hemoglobin (pg)	13.2 (1.7)/29.5 (2.5)
Serum iron (μg/dl)	62 (32)
Serum transferrin (mg/dl)/transferrin saturation (%)	240 (47)/19.5 (10.6)
Total iron-binding capacity/unsaturated iron-binding capacity (μmol/l)	288 (56)/41 (11)
Serum soluble transferrin receptor (mg/l)	3.2 (2.6)
Serum ferritin (ng/ml)	156 (122)
Erythropoietin (mIU/ml)	29.5 (44.4)
TIRD (see Material and Methods) (mg)	808 (323)
NT-proBNP (pg/ml)	5464 (3308)
TNFα (pg/ml)	15.8 (9.7)
hsCRP (mg/dl)	0.72 (0.3)
Serum sodium (mEq/l)	138 (2.5)
Serum creatinine (μmol/l)	108 (35)

LVESV/LVEDV: left ventricle volume end-diastolic/systolic; LVEF: left ventricle ejection fraction; RVD: right ventricle diastolic size; PWP: mean pulmonary wedge pressure; PAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; CI: cardiac index; TIRD: total iron dose required for iron repletion calculated using the Ganzoni formula (see Material and Methods); NT-proBNP: N-terminal pro-B-type natriuretic peptide; TNFα: Tumor Necrosis Factor-alpha; hsCRP: high-sensitivity C-reactive protein.